CA2899763C - Nucleoside phosphoramidate compound and use thereof - Google Patents
Nucleoside phosphoramidate compound and use thereof Download PDFInfo
- Publication number
- CA2899763C CA2899763C CA2899763A CA2899763A CA2899763C CA 2899763 C CA2899763 C CA 2899763C CA 2899763 A CA2899763 A CA 2899763A CA 2899763 A CA2899763 A CA 2899763A CA 2899763 C CA2899763 C CA 2899763C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- phenyl
- alkenyl
- group
- halogenated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310075423 | 2013-03-08 | ||
| CN201310075423.5 | 2013-03-08 | ||
| PCT/CN2014/073004 WO2014135107A1 (zh) | 2013-03-08 | 2014-03-06 | 新的核苷氨基磷酸酯化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2899763A1 CA2899763A1 (en) | 2014-09-12 |
| CA2899763C true CA2899763C (en) | 2020-03-10 |
Family
ID=51462121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2899763A Active CA2899763C (en) | 2013-03-08 | 2014-03-06 | Nucleoside phosphoramidate compound and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9963480B2 (https=) |
| EP (1) | EP2940031B1 (https=) |
| JP (1) | JP6219414B2 (https=) |
| KR (1) | KR101857337B1 (https=) |
| CN (4) | CN108314697B (https=) |
| AU (1) | AU2014225052B2 (https=) |
| BR (1) | BR112015020472B1 (https=) |
| CA (1) | CA2899763C (https=) |
| MX (1) | MX374244B (https=) |
| RU (1) | RU2621709C2 (https=) |
| WO (1) | WO2014135107A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6219414B2 (ja) | 2013-03-08 | 2017-10-25 | ナンジン・サンホーム・ファーマシューティカル・カンパニー・リミテッドＮａｎｊｉｎｇ Ｓａｎｈｏｍｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 新規なヌクレオシドホスホロアミデート化合物およびその使用 |
| CN104761604A (zh) * | 2014-01-02 | 2015-07-08 | 江苏豪森药业股份有限公司 | 尿嘧啶核苷酸类似物及其制备方法和应用 |
| CN105315319B (zh) * | 2014-07-30 | 2020-11-20 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| US10526363B2 (en) | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
| WO2016044243A1 (en) * | 2014-09-16 | 2016-03-24 | Achillion Pharmaceuticals, Inc. | Pyrimidine nucleoside phosphoramidate |
| CN105348342B (zh) * | 2014-09-30 | 2018-09-21 | 南京正大天晴制药有限公司 | 核苷氨基磷酸酯化合物及药物组合物和用途 |
| CN106132972B (zh) * | 2015-02-06 | 2018-08-31 | 银杏树药业(苏州)有限公司 | 用于治疗hcv感染的氨基磷酸酯 |
| CN106866737B (zh) * | 2015-12-11 | 2020-11-20 | 南京圣和药物研发有限公司 | 膦酸衍生物及其应用 |
| DK3512863T3 (da) * | 2016-09-07 | 2022-03-07 | Atea Pharmaceuticals Inc | 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus |
| CN108602842B (zh) * | 2016-11-02 | 2020-10-09 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
| US20190358214A1 (en) * | 2016-11-17 | 2019-11-28 | Abbvie Inc. | Compositions and Methods for Treating HCV Infection |
| CN108218938B (zh) * | 2016-12-13 | 2022-06-07 | 南京圣和药业股份有限公司 | 联苯核苷氨基磷酸酯化合物的晶型及其制备方法与用途 |
| CN108218939B (zh) * | 2016-12-13 | 2022-05-17 | 南京汇诚制药有限公司 | 联苯核苷氨基磷酸酯化合物的新晶型及制备方法 |
| CN108218940A (zh) * | 2016-12-13 | 2018-06-29 | 南京圣和药业股份有限公司 | 核苷氨基磷酸酯类化合物、其制备方法及用途 |
| CN108218936B (zh) * | 2016-12-13 | 2022-06-07 | 南京圣和药业股份有限公司 | 联苯核苷氨基磷酸酯化合物的异构体及其无定型物 |
| CN121221626A (zh) * | 2016-12-13 | 2025-12-30 | 南京汇诚制药有限公司 | 新的核苷氨基磷酸脂化合物的组合物及其制备方法 |
| CN108218937B (zh) * | 2016-12-13 | 2022-06-07 | 南京圣和药业股份有限公司 | 核苷氨基磷酸酯类化合物的光学异构体及其应用 |
| CN108201539B (zh) * | 2016-12-16 | 2022-04-19 | 南京汇诚制药有限公司 | 联苯核苷氨基磷酸酯化合物的应用 |
| CN109419806B (zh) * | 2017-08-23 | 2023-06-20 | 南京圣和药业股份有限公司 | 抗病毒组合物及其应用 |
| CN108997426B (zh) * | 2018-07-19 | 2020-11-13 | 大连理工大学 | 靶向Hsp60的黄酮烷氧基氨基磷酸酯衍生物、制备及应用 |
| EP3997098A4 (en) * | 2019-07-12 | 2023-10-11 | Canopy Growth Corporation | CANNABINOIDS DERIVATIVES |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147175A1 (en) * | 2000-11-16 | 2002-10-10 | Shepard H. Michael | Synergistic ECTA compositions |
| EP2359833A1 (en) * | 2003-04-25 | 2011-08-24 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| CA2584367A1 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| GB0503642D0 (en) | 2005-02-22 | 2005-03-30 | Younane Paul P M | An exercise apparatus |
| AR056327A1 (es) * | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| PA8852101A1 (es) * | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| PT2376088T (pt) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída |
| JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
| BR112013005872A2 (pt) * | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
| EP2755985B1 (en) * | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
| MY171577A (en) * | 2011-12-20 | 2019-10-21 | Hoffmann La Roche | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| JP6219414B2 (ja) | 2013-03-08 | 2017-10-25 | ナンジン・サンホーム・ファーマシューティカル・カンパニー・リミテッドＮａｎｊｉｎｇ Ｓａｎｈｏｍｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 新規なヌクレオシドホスホロアミデート化合物およびその使用 |
| CN104761604A (zh) * | 2014-01-02 | 2015-07-08 | 江苏豪森药业股份有限公司 | 尿嘧啶核苷酸类似物及其制备方法和应用 |
-
2014
- 2014-03-06 JP JP2015560536A patent/JP6219414B2/ja active Active
- 2014-03-06 AU AU2014225052A patent/AU2014225052B2/en active Active
- 2014-03-06 RU RU2015142682A patent/RU2621709C2/ru active
- 2014-03-06 US US14/764,865 patent/US9963480B2/en active Active
- 2014-03-06 WO PCT/CN2014/073004 patent/WO2014135107A1/zh not_active Ceased
- 2014-03-06 KR KR1020157027466A patent/KR101857337B1/ko active Active
- 2014-03-06 MX MX2015011473A patent/MX374244B/es active IP Right Grant
- 2014-03-06 BR BR112015020472-4A patent/BR112015020472B1/pt active IP Right Grant
- 2014-03-06 CA CA2899763A patent/CA2899763C/en active Active
- 2014-03-06 EP EP14760567.9A patent/EP2940031B1/en active Active
- 2014-03-07 CN CN201810261269.3A patent/CN108314697B/zh active Active
- 2014-03-07 CN CN201810261299.4A patent/CN109503686B/zh active Active
- 2014-03-07 CN CN201810261317.9A patent/CN108546277B/zh active Active
- 2014-03-07 CN CN201410081865.5A patent/CN104031104B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2940031A1 (en) | 2015-11-04 |
| CN104031104B (zh) | 2018-04-10 |
| JP6219414B2 (ja) | 2017-10-25 |
| HK1210619A1 (en) | 2016-04-29 |
| MX2015011473A (es) | 2016-05-31 |
| KR101857337B1 (ko) | 2018-05-11 |
| US9963480B2 (en) | 2018-05-08 |
| BR112015020472B1 (pt) | 2021-01-19 |
| CN108546277A (zh) | 2018-09-18 |
| EP2940031A4 (en) | 2016-01-27 |
| JP2016510043A (ja) | 2016-04-04 |
| US20150361123A1 (en) | 2015-12-17 |
| AU2014225052B2 (en) | 2016-11-10 |
| CN109503686A (zh) | 2019-03-22 |
| KR20150132230A (ko) | 2015-11-25 |
| EP2940031B1 (en) | 2017-09-27 |
| RU2621709C2 (ru) | 2017-06-07 |
| CA2899763A1 (en) | 2014-09-12 |
| MX374244B (es) | 2025-03-05 |
| RU2015142682A (ru) | 2017-04-13 |
| CN109503686B (zh) | 2022-03-11 |
| CN104031104A (zh) | 2014-09-10 |
| BR112015020472A2 (pt) | 2020-01-28 |
| AU2014225052A1 (en) | 2015-08-20 |
| CN108546277B (zh) | 2021-05-07 |
| CN108314697A (zh) | 2018-07-24 |
| CN108314697B (zh) | 2021-05-07 |
| WO2014135107A1 (zh) | 2014-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2899763C (en) | Nucleoside phosphoramidate compound and use thereof | |
| KR102453808B1 (ko) | 필로비리다에 바이러스 감염을 치료하는 방법 | |
| JP5735482B2 (ja) | 縮合環のｃ型肝炎阻害剤 | |
| CN102083845B (zh) | 环丙基聚合酶抑制剂 | |
| CA2921899A1 (en) | Hcv polymerase inhibitors | |
| CN104231023B (zh) | 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用 | |
| CN106883280B (zh) | 一种前药、其制备方法、药物组合物及其用途 | |
| CN105315319B (zh) | 丙型肝炎病毒抑制剂及其应用 | |
| BR112021015864A2 (pt) | Sulfonamidas bicíclicas | |
| EP4247800B1 (en) | N-substituted 4-(1,3-aryloxazolo-2-yl)phenyl compounds for the treatment and prophylaxis of hepatitis b virus infection | |
| CN102649788B (zh) | β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途 | |
| WO2017101785A1 (zh) | 一种化合物、其制备方法、药物组合物及其用途 | |
| TWI639613B (zh) | Ｈｃｖ聚合酶抑制劑 | |
| CN107074876B (zh) | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 | |
| HK1210619B (en) | Nucleoside phosphoramidate compounds for use in the treatment of hcv | |
| TW201718608A (zh) | 用於抗ｃ型肝炎病毒感染的含矽化合物 | |
| WO2021209425A9 (en) | Alkynyl nucleoside analogs for treatment of hepatitis e | |
| TW201815396A (zh) | Hcv聚合酶抑制劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150730 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250220 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250220 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260223 |